Total Payments
$381,835
2024 Payments
$74,097
Companies
53
Transactions
556
Medicare Patients
3,389
Medicare Billing
$475,371
Payment Breakdown by Category
Other$319,860 (83.8%)
Research$20,817 (5.5%)
Consulting$15,545 (4.1%)
Travel$12,953 (3.4%)
Food & Beverage$12,316 (3.2%)
Education$342.87 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $319,195 | 91 | 83.6% |
| Unspecified | $20,817 | 5 | 5.5% |
| Consulting Fee | $15,545 | 13 | 4.1% |
| Travel and Lodging | $12,953 | 80 | 3.4% |
| Food and Beverage | $12,316 | 348 | 3.2% |
| Long term medical supply or device loan | $665.16 | 7 | 0.2% |
| Education | $342.87 | 12 | 0.1% |
Payments by Type
General
$361,017
551 transactions
Research
$20,817
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Inc. | $186,245 | 146 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $165,259 | 122 | $0 (2024) |
| Eli Lilly and Company | $20,817 | 5 | $0 (2024) |
| Janssen Biotech, Inc. | $3,333 | 18 | $0 (2020) |
| PFIZER INC. | $1,688 | 46 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $1,283 | 40 | $0 (2024) |
| Genentech USA, Inc. | $285.96 | 30 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $273.28 | 23 | $0 (2023) |
| AstraZeneca UK Limited | $261.74 | 2 | $0 (2023) |
| Eisai Inc. | $220.14 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $74,097 | 53 | Daiichi Sankyo Inc. ($41,057) |
| 2023 | $78,143 | 88 | Daiichi Sankyo Inc. ($44,056) |
| 2022 | $71,216 | 75 | AstraZeneca Pharmaceuticals LP ($35,558) |
| 2021 | $82,383 | 62 | Daiichi Sankyo Inc. ($41,380) |
| 2020 | $57,069 | 59 | AstraZeneca Pharmaceuticals LP ($32,512) |
| 2019 | $16,067 | 71 | Eli Lilly and Company ($10,962) |
| 2018 | $1,118 | 59 | PFIZER INC. ($230.72) |
| 2017 | $1,742 | 89 | Eli Lilly and Company ($376.81) |
All Payment Transactions
556 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $47.84 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,340.00 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,360.00 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Travel and Lodging | In-kind items and services | $251.92 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,680.00 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,680.00 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,020.00 | General |
| Category: ONCOLOGY | ||||||
| 10/08/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $4.76 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Travel and Lodging | In-kind items and services | $81.74 | General |
| Category: ONCOLOGY | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $8,689.00 | Research |
| Study: EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | ||||||
| 09/23/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $123.19 | General |
| Category: ONCOLOGY | ||||||
| 09/19/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Oncology | ||||||
| 09/12/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $62.40 | General |
| Category: Oncology | ||||||
| 09/09/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Oncology | ||||||
| 08/09/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $25.98 | General |
| Category: Oncology | ||||||
| 08/07/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| 07/15/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 06/13/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 06/01/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $25.96 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $10.40 | General |
| Category: Oncology | ||||||
| 05/31/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 05/24/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: ONCOLOGY | ||||||
| 05/24/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Travel and Lodging | In-kind items and services | $171.52 | General |
| Category: ONCOLOGY | ||||||
| 05/21/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,450.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $11,403 | 3 |
| EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | Eli Lilly and Company | $8,689 | 1 |
| EMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+ HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | Eli Lilly and Company | $725.51 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 912 | 1,473 | $290,528 | $135,952 |
| 2022 | 9 | 657 | 1,037 | $203,098 | $92,603 |
| 2021 | 10 | 860 | 1,476 | $285,035 | $134,996 |
| 2020 | 12 | 960 | 1,508 | $269,895 | $111,820 |
Total Patients
3,389
Total Services
5,494
Medicare Billing
$475,371
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 476 | 919 | $170,934 | $82,451 | 48.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 100 | 100 | $28,600 | $11,390 | 39.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 52 | 79 | $19,750 | $10,427 | 52.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 49 | 133 | $17,157 | $8,142 | 47.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 45 | 45 | $16,020 | $7,407 | 46.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 93 | 96 | $12,000 | $5,577 | 46.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 30 | 31 | $11,129 | $4,162 | 37.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 33 | 33 | $8,052 | $3,219 | 40.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 23 | 26 | $4,862 | $2,297 | 47.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 11 | 11 | $2,024 | $878.03 | 43.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 380 | 704 | $130,618 | $60,037 | 46.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 47 | 65 | $16,224 | $8,514 | 52.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 42 | 42 | $14,952 | $6,924 | 46.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 69 | 73 | $9,107 | $4,297 | 47.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 35 | 35 | $10,010 | $3,973 | 39.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 37 | 71 | $9,159 | $3,611 | 39.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 21 | 21 | $7,539 | $3,165 | 42.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 11 | 11 | $2,684 | $1,125 | 41.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 15 | 15 | $2,805 | $956.89 | 34.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 367 | 832 | $153,088 | $74,747 | 48.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 67 | 103 | $25,544 | $13,450 | 52.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 61 | 61 | $21,716 | $9,911 | 45.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 147 | 159 | $19,716 | $9,537 | 48.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 66 | 153 | $19,737 | $8,249 | 41.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 45 | 48 | $17,232 | $7,145 | 41.5% |
About Dr. Stephen Dyar, MD
Dr. Stephen Dyar, MD is a Internal Medicine healthcare provider based in Greenville, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/01/2007. The National Provider Identifier (NPI) number assigned to this provider is 1497883565.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Dyar, MD has received a total of $381,835 in payments from pharmaceutical and medical device companies, with $74,097 received in 2024. These payments were reported across 556 transactions from 53 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($319,195).
As a Medicare-enrolled provider, Dyar has provided services to 3,389 Medicare beneficiaries, totaling 5,494 services with total Medicare billing of $475,371. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine, Hematology & Oncology
- Location Greenville, SC
- Active Since 03/01/2007
- Last Updated 07/21/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1497883565
Products in Payments
- Enhertu (Drug) $150,822
- ENHERTU (Biological) $80,275
- ENHERTU (Drug) $35,288
- LYNPARZA (Drug) $26,551
- Erleada (Drug) $3,211
- KISQALI (Drug) $683.80
- IBRANCE (Drug) $203.62
- Lenvima (Drug) $199.69
- PROMACTA (Drug) $154.40
- KEYTRUDA (Biological) $112.36
- OPDIVO (Biological) $106.05
- Lonsurf (Drug) $100.11
- XTANDI (Drug) $99.94
- IMBRUVICA (Drug) $94.64
- AFINITOR (Drug) $93.02
- JAKAFI (Drug) $87.53
- ZALTRAP (Drug) $84.75
- FERAHEME (Drug) $77.88
- Avastin (Biological) $76.26
- SUTENT (Drug) $75.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Greenville
Dr. John Catanzaro, Md, MD
Internal Medicine — Payments: $331,996
Internal Medicine $331,996
Bhumika Patel, M.d, M.D
Internal Medicine — Payments: $208,547
Internal Medicine $208,547
Dr. Thomas Gallaher, M.d, M.D
Internal Medicine — Payments: $208,355
Internal Medicine $208,355
Bruce Gray, D.o, D.O
Internal Medicine — Payments: $166,102
Internal Medicine $166,102
Dr. Mark Purcell, Do, DO
Internal Medicine — Payments: $135,587
Internal Medicine $135,587
Dr. Jesse Jorgensen, M.d, M.D
Internal Medicine — Payments: $134,042
Internal Medicine $134,042